Jubilant Life Sciences in South Africa

Jubilant Life Sciences Limited Completes Spin-Off of Life Science Ingredients Business

New Delhi, India – October 25, 2023

Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, has successfully completed the spin-off of its Life Science Ingredients (LSI) business into a separate entity. The newly formed company, Jubilant Ingrevia Limited, will focus on the production of specialty chemicals, nutrition and health solutions, and chemical intermediates. This strategic move aims to enhance operational focus and unlock shareholder value by allowing investors to directly participate in each business segment. (marketscreener.com)

Jubilant Life Sciences Limited Renamed Jubilant Pharmova Limited

New Delhi, India – October 25, 2023

In conjunction with the demerger, Jubilant Life Sciences Limited has rebranded itself as Jubilant Pharmova Limited. The company will continue to operate its pharmaceutical and drug discovery services under this new name, reflecting its commitment to innovation and growth in the pharmaceutical sector. (uk.marketscreener.com)

Jubilant Life Sciences Enters Licensing Agreement with Gilead for Remdesivir

New Delhi, India – December 4, 2020

Jubilant Life Sciences Limited’s subsidiary, Jubilant Generics Limited, has entered into a non-exclusive licensing agreement with Gilead Sciences. This agreement grants Jubilant the rights to register, manufacture, and sell Gilead’s investigational drug, remdesivir, in 127 countries, including India. The partnership aims to expedite access to this potential COVID-19 therapy, pending regulatory approvals. (financialexpress.com)

Jubilant Life Sciences Raises ₹350 Crore Through Non-Convertible Debentures

New Delhi, India – October 30, 2019

Jubilant Life Sciences Limited successfully raised ₹350 crore through the issuance of 3,500 non-convertible debentures (NCDs), each valued at ₹10 lakh. The funds are intended for the repayment of existing debt and to reduce the overall cost of borrowing. The NCDs have a maturity period of 2 to 4 years, with interest rates ranging between 8.95% and 9.26% per annum. (zeebiz.com)

Jubilant Life Sciences and Norgine Announce Discovery Collaboration in Gastrointestinal Therapeutics

Bengaluru, India – October 25, 2019

Jubilant Biosys Ltd., a subsidiary of Jubilant Life Sciences, has entered into a three-year discovery partnership with Norgine, a European specialty pharmaceutical company. The collaboration aims to develop multiple targets in the gastrointestinal therapeutic area, leveraging Jubilant’s integrated drug discovery platform. Under the agreement, Jubilant will deliver preclinical candidates to Norgine, which will retain all rights to further development and commercialization. (worldpharmatoday.com)

Jubilant Life Sciences and Nuscience Announce Strategic Marketing Agreement

New Delhi, India – May 25, 2016

Jubilant Life Sciences Limited and Nuscience Group have entered into a strategic marketing collaboration for the distribution of Nuscience products in India, Sri Lanka, and Nepal. Jubilant will market Nuscience’s Health4U products, targeting the poultry industry, to benefit breeders, broiler integrators, and grandparent farms in these regions. (wattagnet.com)

These developments highlight Jubilant Life Sciences Limited’s ongoing efforts to strengthen its position in the global pharmaceutical and life sciences sectors through strategic partnerships, financial initiatives, and organizational restructuring.